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Introduction {#sec001}
============

Neuronal differentiation is a complex process coordinated by the down-regulation of pluripotent genes and concomitant up-regulation of neuron-specific lineage genes. Established cell culture models are frequently used to study *in vitro* neuronal differentiation. These models exhibit neuron-like morphology and express neuronal marker mRNAs and proteins in response to several neurotrophins, growth factors, and chemical compounds. Rat adrenal pheochromocytoma cells (PC12) differentiate into sympathetic neuron-like cells, which are characterized by neurite outgrowth, electrical excitability, and expression of neuronal markers in response to nerve growth factor (NGF) \[[@pone.0141581.ref001]--[@pone.0141581.ref003]\]. Mouse neuroblastoma cells (Neuro-2A) exhibited neuron-like morphology in the presence of the cannabinoid receptor agonist HU-210 \[[@pone.0141581.ref004], [@pone.0141581.ref005]\]. In human neuroblastoma cell lines (SK-N-SH, BE(2)-C, and NB1643), all-trans retinoic acid induced neurite outgrowth and expression of neuronal markers \[[@pone.0141581.ref006], [@pone.0141581.ref007]\]. Recently, adult tissue stem cells have been reported to possess neuronal differentiation potency, and considered as a useful tool for neuronal differentiation research \[[@pone.0141581.ref008], [@pone.0141581.ref009]\].

Bone marrow stromal cells (BMSCs) are fibroblastic adherent cells isolated from the bone marrow in adult human and animals such as mouse and dogs. Similar to other stem cell types, BMSCs have a high capacity for self-renewal, and are capable of differentiating into mesodermal cells, including adipocytes, chondrocytes, osteocytes, and ectodermal cells such as neurons and glial cells \[[@pone.0141581.ref010]--[@pone.0141581.ref014]\]. Cells undergo the following three steps in their differentiation into mature neurons: commitment of an ectodermal lineage, specialization of the neuronal lineage, and maturation of neuron characteristics. Previous studies using several animal models found that *in vitro* neuronal differentiation follows the processes of *in vivo* neuronal development, which are related to the surrounding microenvironments. Therefore, the arrangement of a proper microenvironment for the neuronal development process is essential to induce BMSCs into neurons. Treatment of rat BMSCs with chemical compounds such as β-mercaptoethanol and butylated hydroxyanisole resulted in the expression of neuron markers and neuron-like morphological changes \[[@pone.0141581.ref015]\]. Similarly, mice BMSCs treated with β-mercaptoethanol and brain-derived neurotrophic factor (BDNF) expressed neuron marker mRNAs, exhibited neuron-like morphologies, and voltage-dependent inward currents \[[@pone.0141581.ref016]\]. In human BMSCs, β-mercaptoethanol, butylated hydroxyanisole, and retinoic acid induced the expression of neuron marker mRNAs and proteins, but failed to induce the exhibition of voltage-dependent Na^+^ current \[[@pone.0141581.ref017]\]. On the other hand, human BMSCs were reported to express neuron marker mRNAs and proteins and exhibit functional α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors using cAMP, 3-isobutyl-1-methylxanthine, NGF and insulin \[[@pone.0141581.ref018]\].

Basic fibroblast growth factor (bFGF) functions as a differentiation factor as well as a neurotrophic factor in the central nervous system, where it is highly expressed. It supports cell survival, growth, and differentiation. \[[@pone.0141581.ref019]--[@pone.0141581.ref021]\]. bFGF contributes to the specification of the neuronal lineage in the *in vitro* neuronal differentiation process along with other extracellular molecules. In mouse BMSCs treated with bFGF, neuron-specific proteins, functional dopamine receptors, and voltage-dependent channels were expressed, and neuron-like K^+^ outward currents were detected \[[@pone.0141581.ref022], [@pone.0141581.ref023]\]. In human BMSCs, bFGF contributed to differentiation of BMSCs into functional neuron-like cells; these BMSCs expressed neuron-specific mRNAs and proteins as well as exerted voltage-responsive and dopamine-secreting neuron-like functions \[[@pone.0141581.ref024]--[@pone.0141581.ref027]\]. Moreover, we have previously reported that canine BMSCs treated with bFGF alone expressed neuron-specific mRNAs (microtubule associated protein-2 \[*MAP2*\], neurofilament light chain, and neuron-specific enolase) and proteins (neurofilament light chain and neuron-specific enolase), and exhibited neuron-like morphology. In the bFGF-treated canine BMSCs, KCl and L-glutamate evoked a sharp rise in intracellular Ca^2+^ concentrations, suggesting that bFGF induced differentiation of canine BMSCs into voltage- and glutamate-responsive neuron-like cells \[[@pone.0141581.ref028]\].

bFGF activates several signaling pathways such as MAPK/ERK kinase (MEK)/Extracellular signal-regulated kinase (ERK) pathway. In mouse BMSCs, bFGF induces neuronal differentiation via the MEK/ERK pathway \[[@pone.0141581.ref023]\]; therefore, activation of this pathway is considered crucial in bFGF-induced neuronal differentiation of mouse BMSCs. bFGF also activates the phosphoinositide 3-kinase (PI3K)/Akt pathway. Furthermore, bFGF mediates cell survival via the PI3K/Akt pathway in mouse models of neuronal differentiation, embryonic carcinoma cell lines (P19 cells), embryonic stem cells, and primary neural stem cells \[[@pone.0141581.ref029]\]. In PC12 cells, bFGF suppressed endoplasmic reticulum stress-induced apoptosis via the PI3K/Akt pathway \[[@pone.0141581.ref030], [@pone.0141581.ref031]\]. In this study, we examined the role of activation of PI3K/Akt pathway in bFGF-induced neuronal differentiation of canine BMSCs.

Materials and Methods {#sec002}
=====================

Isolation and Culture of Canine BMSCs {#sec003}
-------------------------------------

This study was approved by the Nihon University Animal Care and Use Committee (AP12B015). Three healthy beagles (male, 3 years old) were purchased from Japan SLC Inc., and bred and maintained in cages (height: 137 cm; width: 80 cm; length: 86 cm). The experimental food TC-2 (250 g/head; Oriental Yeast Co. Ltd.) was provided to all study animals once a day. The dogs were exercised using some toys inside (once a day) and outside (once a month) of the animal breeding facility. The physical conditions of the facility were monitored once a day. To avoid infection, the dogs were housed distantly from each other. All efforts were made to improve animal welfare and minimize discomfort. The dogs were premedicated with an intravenous injection of midazolam hydrochloride (0.2 mg/kg; Astellas Pharma Inc., Tokyo, Japan) and butorphanol tartrate (0.2 mg/kg; Meiji Seika Pharma Co. Ltd., Tokyo, Japan). Anesthesia was induced intravenously with propofol (4.0 mg/kg; Intervet K.K, Osaka, Japan) and maintained with 2.0% isoflurane (Intervet K.K.) and 100% oxygen was provided in an endotracheal tube. To minimize potential pain and infection, butorphanol tartrate (0.2 mg/kg) and cefazolin sodium hydrate (20 mg/kg, Astellas Pharma Inc.) were administered intravenously before awakening. Canine BMSCs were isolated by a previously described method \[[@pone.0141581.ref028], [@pone.0141581.ref032]--[@pone.0141581.ref034]\]. Briefly, canine bone marrow was aspirated from the humerus and mononuclear cells were separated by density-gradient centrifugation using Histopaque-1077 (Sigma-Aldrich Inc., St. Louis, MO). Thereafter, the mononuclear cells were then transferred to a 75-cm^2^ plastic culture flask (Thermo Fisher Scientific, Inc., St. Waltham, MA) and static-cultured in an incubator at 5% CO~2~ and 37°C using α-modified Eagle minimum essential medium (Life Technologies Co., Carlsbad, CA) supplemented with 10% fetal bovine serum (Life Technologies Co.). On the fourth day of culture, nonadherent cells were removed when the culture medium was replaced, thus isolating canine BMSCs. The cells were harvested using 0.25% trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; Life Technologies Co.) once they reached approximately 90% confluence. Then, the collected cells were seeded at a density of 14,000 cells/cm^2^. The second-passage canine BMSCs were used for all subsequent experiments.

Neuronal Induction Using bFGF {#sec004}
-----------------------------

Canine BMSCs were placed in a 25-cm^2^ plastic culture flask (Thermo Fisher Scientific, Inc.) at a density of 4,000 cells/cm^2^. bFGF-induced neuronal differentiation was performed as described previously \[[@pone.0141581.ref028]\]. In brief, the medium was changed to Neurobasal-A medium (Life Technologies Co.) supplemented with 2% B-27 supplement (Life Technologies Co.) and 100 ng/ml recombinant human bFGF (Immunostep, Salamanca, Spain) at 24 h of passage.

Inhibitor Treatment {#sec005}
-------------------

Canine BMSCs were placed in a 25-cm^2^ plastic culture flask at a density of 4,000 cells/cm^2^. The cells were pretreated with Neurobasal-A medium with 2% B-27 supplement containing the fibroblast growth factor receptor (FGFR) inhibitor SU5402 (20 μM; Sigma-Aldrich Inc.), the PI3K inhibitor LY294002 (50 μM; Cell Signaling Technology Japan K.K., Tokyo, Japan), the Akt inhibitor MK2206 (1 μM; Selleck Chemicals Llc., Houston, TX), the PLC inhibitor U73122 (8 μM; Sigma-Aldrich Inc.), or the MEK/ERK inhibitor U0126 (20 μM; Sigma-Aldrich Inc.) for 1 h, following a slightly modified version of previously reported methods \[[@pone.0141581.ref023]\]. Next, cells were treated with bFGF as described above. After 3 days of bFGF treatment, total RNA was extracted from each sample, which was then subjected to real-time RT-PCR to evaluate mRNA expression of *MAP2*.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) {#sec006}
--------------------------------------------------------

Total RNA was extracted from canine BMSCs using TRIzol^®^ reagent (Life Technologies Co.) according to the manufacturer's instructions. Total RNA concentration was measured spectrophotometrically by reading absorbance at 260/280 nm. First-strand cDNA synthesis was carried out using 500 ng of total RNA using the PrimeScript RT Master Mix (TaKaRa Bio Inc., Shiga, Japan). PCRs were performed using 2 μl of first-strand cDNA in 10 μl total reaction volume, with primers specific for canine FGF receptor (FGFR)-1, FGFR-2, FGFR-3 and FGFR-4 ([Table 1](#pone.0141581.t001){ref-type="table"}) and Ex Taq (TaKaRa Bio Inc.). PCRs were conducted using iCycler (Bio-Rad, Hercules, CA). The thermal cycler was programmed for initial denaturation at 94°C for 2 min, followed by 25 cycles of denaturation at 94°C for 30 sec, primer annealing at 55°C for 30 sec, and primer extension at 72°C for 30 sec. The PCR products were separated using 2% agarose gel electrophoresis, followed by ethidium bromide staining and visualization under UV light. mRNA expression levels in each sample were normalized to that of TATA box-binding protein \[*TBP*\].

10.1371/journal.pone.0141581.t001

###### Primers used for RT-PCR.

![](pone.0141581.t001){#pone.0141581.t001g}

  Gene Name   GenBank ID       Primer sequences
  ----------- ---------------- ------------------------------------
  *FGFR-1*    XM_003639562.1   F: 5′-ACCAAAGTGGCCGTGAAGATG-3′
                               R: 5′-CAGCAGGTTGATGATGTTCTTGTG-3′
  *FGFR-2*    NM_001003336.1   F: 5′-TCGAGGGTGGACCTTAGTTGAGA-3′
                               R: 5′-TCAGTGTTTCAATTTCGACGATGAC-3′
  *FGFR-3*    XM_545926.3      F: 5′-CTGGTGTCTGAGATGGAGATGATGA-3′
                               R: 5′-GCAGGTATTCCCGCAGGTTG-3′
  *FGFR-4*    XM_003434496.1   F: 5′-CAGAGGCCTTTGGCATGGA-3′
                               R: 5′-TTATGTCGGCCGATCAGCTTC-3′
  *TBP*       XM_863452        F: 5′-ACTGTTGGTGGGTCAGCACAAG-3′
                               R: 5′-ATGGTGTGTACGGGAGCCAAG-3′

Real-Time RT-PCR {#sec007}
----------------

Real-time RT-PCRs were performed as previously reported \[[@pone.0141581.ref028], [@pone.0141581.ref034]\]. Total RNAs were extracted from canine BMSCs using TRIzol^®^ reagent (Life Technologies Co.) according to the manufacturer's instructions. First-strand cDNA synthesis was performed using 500 ng of total RNA, using PrimeScript^®^ RT Master Mix (TaKaRa Bio Inc.). Real-time RT-PCRs were performed with 2 μl of the first-strand cDNA in 25 μl total reaction volume, with canine-specific primers for the neuron marker *MAP2* ([Table 2](#pone.0141581.t002){ref-type="table"}) and SYBR^®^ Premix Ex Taq™ II (TaKaRa Bio Inc.). The real-time RT-PCRs of no template controls were performed with 2 μl of RNase- and DNA-free water. In addition, real-time PCRs of no-reverse transcription controls were performed using 2 μl of each RNA sample. The PCRs were conducted using Thermal Cycler Dice^®^ Real Time System II (TaKaRa Bio Inc.). The PCR reactions consisted of 1 cycle of denaturing at 95°C for 30 sec, followed by 40 cycles of denaturing at 95°C for 5 sec and annealing and extension at 60°C for 30 sec. The specificity of each primer was previously verified using dissociation curve analysis and direct sequencing of each PCR product \[[@pone.0141581.ref034]\]. The results were analyzed by means of the second derivative method and the comparative cycle threshold method using TP900 DiceRealTime v4.02B (TaKaRa Bio Inc.). Amplification of β-glucuronidase (*GUSB*) from the same amount of cDNA was used as an endogenous control.

10.1371/journal.pone.0141581.t002

###### Primers used for Real-time RT-PCR.

![](pone.0141581.t002){#pone.0141581.t002g}

  Gene Name   GenBank ID       Primer sequences
  ----------- ---------------- ---------------------------------
  *MAP2*      XM_845165.1      F: 5′-AAGCATCAACCTGCTCGAATCC-3′
                               R: 5′-GCTTAGCGAGTGCAGCAGTGAC-3′
  *GUSB*      NM_001003191.1   F: 5′-ACATCGACGACATCACCGTCA-3′
                               R: 5′-GGAAGTGTTCACTGCCCTGGA-3′

Cross-Linking and Immunoprecipitation {#sec008}
-------------------------------------

Cross-linking and immunoprecipitation (CLIP) was performed as described previously \[[@pone.0141581.ref023]\], with some modifications. After incubation with bFGF (100 ng/ml) for 2 min, canine BMSCs were washed twice with cold PBS and cross-linked with 1 mM dithiobis(sulfosuccinimidyl propionate) disodium salt (DTSSP) at 4°C for 2 h. A fresh DTSSP stock solution was prepared in dimethyl sulfoxide. The reactions were terminated by the addition of glycine (final concentration of 100 mM) and incubation at room temperature for 15 min. The cells were washed twice with cold PBS and then lysed with lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, 1% Triton X-100, 2.5 mM Na~4~P~2~O~7~, 1 mM β-glycerophosphate, 1 mM Na~3~VO~4~, 1 mM phenylmethylsulfonyl fluoride, and complete mini EDTA-free protease inhibitor cocktail; from Roche, Mannheim, Germany) and centrifuged at 14,000 *g* for 20 min at 4°C. The proteins in the supernatant were quantified using DC™ protein assay reagent kit (Bio-Rad). For immunoprecipitation analysis, 500 μg of total cell lysates was precleared with protein A plus G Sepharose (GE Healthcare, Piscataway, NJ) before incubation with specific antibodies, followed by addition of protein A plus G Sepharose. Total cell lysate was incubated with 5 μg anti-bFGF antibody (Sigma-Aldrich Inc.) at 4°C for 18 h. The precipitated proteins were dissolved in sodium dodecyl sulfate (SDS) sample buffer before electrophoresis. Finally, the precipitated proteins were incubated in the presence or absence 200 mM dithiothreitol (DTT) and analyzed by western blotting with anti-FGFR-1 antibody (Abcam Plc., Cambridge, UK) or FGFR-2 antibody (Abcam Plc.).

Western Blotting {#sec009}
----------------

Canine BMSCs before and after bFGF treatment were lysed with the lysis buffer containing 20 mM HEPES, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, and complete mini EDTA-free protease inhibitor cocktail (Roche, Mannheim, Germany) at pH 7.4. Canine brain lysate obtained using the same lysis solution was used as a positive control for FGFR-1 and FGFR-2. Protein concentrations were normalized in accordance with Bradford's method \[[@pone.0141581.ref035]\]. Extracted proteins were boiled at 95°C for 5 min in SDS-DTT buffer. Samples containing 30 μg of protein were loaded in each lane of a 7.5% polyacrylamide gel (Mini-PROTEAN TGX gel; Bio-Rad) and separated via electrophoresis. Thereafter, the separated proteins were transferred onto polyvinylidene difluoride membranes using Trans-Blot Turbo Transfer System (Bio-Rad). The membranes were blocked at room temperature for 50 min in Block Ace (DS Pharma Biomedical, Osaka, Japan), and then incubated with anti-FGFR-1 (1:250), FGFR-2 (1:1,000), phosphorylated Akt (p-Akt; Cell Signaling Technology Japan K.K., Tokyo, Japan, 1:1,000) or total Akt (t-Akt; Cell Signaling Technology Japan K.K., 1:1,000) antibody for 120 min at room temperature. After washing, the membranes were incubated with a horseradish peroxidase-conjugated anti-mouse, rabbit or goat IgG (GE Healthcare, 1:10,000) at room temperature for 90 min. Immunoreactivity was detected with ECL Western blotting Analysis System (GE Healthcare). The chemiluminescent signals of the membranes were measured, and densitometric analyses were performed using ImageQuant LAS 4000 mini (GE Healthcare).

Small Interfering RNA (siRNA) {#sec010}
-----------------------------

Canine BMSCs (4,000 cells/cm^2^) were placed in a 90-mm diameter plastic dish (Thermo Fisher Scientific, Inc.). The cells were transfected with 33 nM FGFR-2 siRNA (Sigma-Aldrich Inc.; [Table 3](#pone.0141581.t003){ref-type="table"}) or 33 nM scramble siRNA (Sigma-Aldrich Inc.) as scramble control, combined with Lipofectamine 2000 (Life Technologies Co.) for 24 h, and then, bFGF treatment was performed as described above. After the treatment, total RNAs and proteins were extracted from each sample. Real-time RT-PCRs were performed to evaluate the mRNA expression of *FGFR-2*, and western blotting was performed to evaluate the phosphorylation of Akt (as described above).

10.1371/journal.pone.0141581.t003

###### siRNA sequence for canine FGFR-2.

![](pone.0141581.t003){#pone.0141581.t003g}

  Gene Name   GenBank ID       siRNA sequences
  ----------- ---------------- ------------------------------
  FGFR-2      NM_001003336.1   5ʹ-GAGAUAGCCAUUUACUGCATT-3ʹ.

Statistical Analysis {#sec011}
--------------------

Data are presented as mean ± standard error (SE). Statistical analyses were performed using StatMate IV (ATMS, Tokyo, Japan). Data were analyzed using two-way analysis of variance. Tukey's test was used as post-hoc analysis, and *P*-values less than 0.05 were considered statistically significant.

Results {#sec012}
=======

bFGF Induces Neuronal Differentiation of Canine BMSCs via FGFR {#sec013}
--------------------------------------------------------------

We have previously reported that mRNA expression of the neuron marker *MAP2* and neuron-like morphology were observed in bFGF-induced neuronal cell differentiation of canine BMSCs by bFGF \[[@pone.0141581.ref028]\]. Therefore, to elucidate the signaling pathway involved in bFGF-induced neuronal differentiation of canine BMSCs, we first examined the effect of the FGFR inhibitor SU5402 (20 μM) on bFGF-induced *MAP2* mRNA expression. bFGF significantly induced *MAP2* mRNA expression in the absence of this inhibitor, but its effect was attenuated in the presence of the inhibitor ([Fig 1A](#pone.0141581.g001){ref-type="fig"}). Basal *MAP2* mRNA expression was unaffected by the inhibitor compared to untreated cells, and the expression of the housekeeping gene *GUSB* remained stable for 3 days.

![The FGFR inhibitor SU5402 attenuates bFGF-induced *MAP2* mRNA expression and neuron-like morphological change of canine BMSCs.\
A, After pretreatment with SU5402 (20 μM) for 1 h, canine BMSCs were incubated with bFGF (100 ng/ml) for 3 days. SU5402 completely suppressed bFGF-induced *MAP2* mRNA expression. Results are presented as means ± SE. n = 3. \**P* \< 0.05. B, The morphology of untreated canine BMSCs was flattened and fibroblast-like. C, bFGF-treated cells exhibited neuron-like morphology, which was characterized by small cell bodies (arrowheads) and several long sharp processes like dendrites and axons (arrows). D, bFGF-induced morphological changes of the cells were inhibited in the presence of SU5402, which maintained a fibroblast-like shape.](pone.0141581.g001){#pone.0141581.g001}

Next, we checked the effect of the FGFR inhibitor on morphological changes of bFGF-treated cells. Untreated canine BMSCs exhibited a flattened and fibroblast-like morphology ([Fig 1B](#pone.0141581.g001){ref-type="fig"}). bFGF treatment resulted in canine BMSCs exhibiting neuron-like morphology, which was characterized by a small cell body and several long and sharp processes; this change was observed within 3 days of treatment ([Fig 1C](#pone.0141581.g001){ref-type="fig"}). However, the FGFR inhibitor inhibited the bFGF-induced neuron-like morphological changes ([Fig 1D](#pone.0141581.g001){ref-type="fig"}). No effect of these inhibitors on the viability of BMSCs was verified by trypan blue exclusion assay. The FGFR inhibitor was previously reported to attenuate the bFGF-induced neuron marker expression and morphological changes in mouse BMSCs \[[@pone.0141581.ref023]\]. In rat microglia, the FGFR inhibitor inhibited bFGF-promoted generation of MAP2-positive cells \[[@pone.0141581.ref036]\]. Therefore, our observations suggest that bFGF-induced neuronal differentiation in canine BMSCs is largely dependent on FGFR.

Binding of bFGF with FGFR-2 {#sec014}
---------------------------

Four subtypes of FGFRs have been identified in mammals \[[@pone.0141581.ref037]\]; therefore, to determine which of these subtypes contributes to the specific neurogenic effects of bFGF in canine BMSCs, we examined the mRNA and protein expression of FGFR subtypes. mRNA expression of *FGFR-1* and *FGFR-2* was detectable, whereas that of *FGFR-3* and *FGFR-4* was undetectable by RT-PCR experiments using canine BMSCs ([Fig 2A](#pone.0141581.g002){ref-type="fig"}). Expression of FGFR-1 and FGFR-2 proteins in canine BMSCs was confirmed by western blotting ([Fig 2B](#pone.0141581.g002){ref-type="fig"}); these results suggested that FGFR-1 and FGFR-2 are the major subtypes of FGFR in canine BMSCs.

![Expression of various FGFR subtypes and binding of bFGF to these subtypes in canine BMSCs.\
A, mRNA expression of four different subtypes of FGFR determined by RT-PCR using total RNA extracted from canine BMSCs. PCR products for *FGFR-1* and *FGFR-2* were detected to be 120 and 193 bp, respectively. *TBP* control was used as an internal standard for the PCR analysis. B, Detection of FGFR-1 and FGFR-2 proteins (arrowheads) by western blotting using anti-FGFR-1 and anti-FGFR-2 antibodies. Canine brain extracts served as positive controls. C, Canine BMSCs were incubated with bFGF (100 ng/ml) for 2 min and cross-linked with DTSSP (1 mM) at 4°C for 2 h. Whole-cell proteins were extracted and immunoprecipitated with anti-bFGF antibody. Finally, the precipitated bFGF/FGFR complex was treated in the presence or absence DTT (200 mM) and detected by western blotting with anti-FGFR-1 or anti-FGFR-2 antibody. FGFR-2 protein was clearly detected after CLIP in the absence of DTT as indicated by an arrowhead.](pone.0141581.g002){#pone.0141581.g002}

Because bFGF is known to show varying binding affinities for various FGFR subtypes \[[@pone.0141581.ref038]\], we further analyzed binding of bFGF with FGFR subtypes by CLIP experiments. After incubation with bFGF, FGFR-2 was clearly detectable by the CLIP experiments, whereas FGFR-1 was undetectable ([Fig 2C](#pone.0141581.g002){ref-type="fig"}). These results indicate that bFGF mainly bound to FGFR-2 on the surface of BMSCs.

bFGF Induced Neuronal Differentiation Depends on the Activation of PI3K/Akt Pathway {#sec015}
-----------------------------------------------------------------------------------

To investigate the downstream signaling pathway of FGFR in canine BMSCs, we examined effect of the PI3K inhibitor LY294002 (50 μM), the Akt inhibitor MK2206 (1 μM), and the MEK/ERK inhibitor U0126 (20 μM) on bFGF-induced *MAP2* mRNA expression. bFGF significantly induced *MAP2* mRNA expression in the absence of these inhibitors ([Fig 3A](#pone.0141581.g003){ref-type="fig"}). In the presence of the PI3K and Akt inhibitors, the bFGF-induced *MAP2* mRNA expression was attenuated ([Fig 3A](#pone.0141581.g003){ref-type="fig"}). However, the MEK/ERK inhibitor had no effect on the bFGF-induced *MAP2* mRNA expression ([Fig 3A](#pone.0141581.g003){ref-type="fig"}). The expression of the housekeeping gene *GUSB* remained stable for 3 days.

![PI3K and Akt inhibitors, but not PLC and MEK/ERK inhibitors, attenuate bFGF-induced *MAP2* mRNA expression and neuron-like morphological changes in canine BMSCs.\
A, BMSCs pretreated with the PI3K inhibitor LY294002 (50 μM), the Akt inhibitor MK2206 (1 μM), the MEK/ERK inhibitor U0126 (20 μM), and the PLC inhibitor U73122 (8 μM) for 1 h were incubated with bFGF (100 ng/ml) for 3 days. bFGF-induced *MAP2* mRNA expression was completely inhibited in cells treated with LY294002 and MK2206, but not in cells treated with U0126 and U73122. Results are presented as means ± SE. n = 3. \**P* \< 0.05. B, Untreated canine BMSCs exhibited fibroblast-like morphology, which had flattened cell body. C, In the presence of bFGF, the cells exhibited neuron-like morphology, characterized by small cell bodies (arrowheads) and several long sharp processes such as dendrites and axons (arrows). D-F, In the presence of the PI3K (D) and Akt inhibitors (E), bFGF-induced morphological changes of the cells were inhibited, which maintained fibroblast-like shape.](pone.0141581.g003){#pone.0141581.g003}

We next investigated the morphology of bFGF-treated cells in the presence of PI3K and Akt inhibitors. Canine BMSCs showed fibroblast-like shape in the absence of bFGF ([Fig 3B](#pone.0141581.g003){ref-type="fig"}). The bFGF-treated cells exhibited neuron-like morphology within 3 days of treatment ([Fig 3C](#pone.0141581.g003){ref-type="fig"}). In the presence of the PI3K and Akt inhibitors, bFGF failed to induce neuron-like morphological change ([Fig 3D and 3E](#pone.0141581.g003){ref-type="fig"}). Furthermore, no effect of these inhibitors on viability of the cells was verified by the trypan blue exclusion assay.

The MEK/ERK inhibitor U0126 is known to inhibit bFGF-induced neuronal differentiation of mouse BMSCs \[[@pone.0141581.ref023]\]. However, in the present study, unlike the PI3K and Akt inhibitors, the MEK/ERK inhibitor had no effect on the bFGF-induced neuronal differentiation of canine BMSCs. These results suggest that the signaling pathway of neuronal differentiation in canine BMSCs differs from that previously reported in a mouse model, which depends on the activation of the PI3K/Akt pathway.

bFGF induces Akt phosphorylation through FGFR and PI3K {#sec016}
------------------------------------------------------

A serine/threonine kinase Akt is a downstream target of PI3K and is activated by phosphorylation within the carboxy-terminus at serine 473 \[[@pone.0141581.ref039]\]. To verify whether bFGF activates the PI3K/Akt pathway, we examined the activation of Akt using an anti-p-Akt antibody. Akt phosphorylation occurred after bFGF treatment in a time-dependent manner, which peaked at 10 min ([Fig 4](#pone.0141581.g004){ref-type="fig"}). To confirm whether the Akt phosphorylation is dependent on FGFR and PI3K, we examined the effects of the FGFR inhibitor SU5402, the PI3K inhibitor LY294002 and the Akt inhibitor MK2206 on bFGF-induced Akt phosphorylation. We found that all three inhibitors completely inhibited bFGF-induced phosphorylation of Akt ([Fig 5](#pone.0141581.g005){ref-type="fig"}). These observations strongly suggest that bFGF induces activation of Akt by its phosphorylation via FGFR and PI3K.

![bFGF stimulates Akt phosphorylation in canine BMSCs.\
Western blotting for detection of phosphorylated Akt (p-Akt) in BMSCs treated with bFGF (100 ng/ml) for the indicated times (upper panel). Relative density of p-Akt compared with the results at 0 time (lower panel). Relative density of total Akt (t-Akt) compared with the results at 0 time (lower panel). bFGF stimulated the phosphorylation of Akt in a time-dependent manner. Results are presented as means ± SE. n = 3. \**p* \< 0.05.](pone.0141581.g004){#pone.0141581.g004}

![FGFR, PI3K, and Akt inhibitors attenuate bFGF-induced Akt phosphorylation.\
After pretreatment with the FGFR inhibitor SU5402 (25 μM), the PI3K inhibitor LY294002 (50 μM), and the Akt inhibitor MK2206 (1 μM) for 1 h, BMSCs were incubated with bFGF (100 ng/ml) for 10 min. Phosphorylation of Akt was examined by western blotting. The inhibitors of FGFR, PI3K, and Akt completely suppressed bFGF-induced Akt phosphorylation (arrowheads).](pone.0141581.g005){#pone.0141581.g005}

FGFR-2 Contributes to bFGF-Induced Akt Activation {#sec017}
-------------------------------------------------

To elucidate whether FGFR-2 plays a central role in the activation of the PI3K/Akt pathway, we performed an FGFR-2 knockdown experiment using FGFR-2 siRNA transfection. As shown in [Fig 6A](#pone.0141581.g006){ref-type="fig"}, *FGFR-2* mRNA expression was significantly decreased by FGFR-2 siRNA transfection, but not by control and scramble siRNA transfection. Thereafter, we examined for Akt phosphorylation in control cells, scramble siRNA-transfected cells, and FGFR-2 siRNA-transfected cells. Akt phosphorylation was clearly inhibited by FGFR-2 siRNA transfection compared with the control, but to a lesser extent by scramble siRNA transfection ([Fig 6B](#pone.0141581.g006){ref-type="fig"}). These results strongly suggest that FGFR-2 activation contributes to activation of the PI3K/Akt signaling pathway, which attributes to bFGF-induced neuronal differentiation of canine BMSCs.

![FGFR-2 siRNA inhibits the bFGF-induced neuronal differentiation signaling pathway.\
A, FGFR-2 siRNA transfection of canine BMSCs resulted in a significant decrease of *FGFR-2* mRNA expression but not control or scramble siRNA transfection. B, Western blotting for detection of bFGF-induced Akt phosphorylation in control, scramble siRNA-transfected, or FGFR-2 siRNA-transfected cells. FGFR-2 siRNA transfection clearly inhibited the bFGF-induced Akt phosphorylation compared with the control, but to a lesser extent scramble siRNA.](pone.0141581.g006){#pone.0141581.g006}

Discussion {#sec018}
==========

In this study, we demonstrated that FGFR-2 activation contributes to bFGF-induced neuronal differentiation through the activation of the PI3K/Akt signaling pathway in canine BMSCs.

In humans, rodents, and other species, such as zebrafish, amphibians, and chickens, four subtypes of FGFR, FGFR-1 through FGFR-4, have been identified \[[@pone.0141581.ref040]--[@pone.0141581.ref042]\]. In canine BMSCs, we previously demonstrated that bFGF predominantly bound to FGFR-2, which is thought to be mostly associated with neuronal development in mammals \[[@pone.0141581.ref040], [@pone.0141581.ref043]\]. An *FGFR-2* null mutation in mice causes early mortality, prior to the formation of a mature central nervous system \[[@pone.0141581.ref040], [@pone.0141581.ref043]\]. Mutations in *FGFR-2* lead to aberrant neuronal development or to neuronal diseases in humans, such as megalocephaly, midline disorders, hippocampal malformations, and ventricular wall alterations \[[@pone.0141581.ref044], [@pone.0141581.ref045]\]. Therefore, FGFR-2 is likely to be involved in the bFGF-induced neuronal differentiation of canine BMSCs.

bFGF has previously been reported to activate MEK/ERK pathways and consequently induce neuronal differentiation in rat pheochromocytoma cells (PC12), mouse or human neuroblastoma cell lines (Neuro2A, SK-N-SH and BE(2)-C), and embryonic stem cells \[[@pone.0141581.ref002], [@pone.0141581.ref003], [@pone.0141581.ref005], [@pone.0141581.ref007], [@pone.0141581.ref046]\]. In mouse BMSCs, a MEK/ERK inhibitor attenuated bFGF-induced neuronal differentiation, but a PI3K inhibitor failed to induce the bFGF effect \[[@pone.0141581.ref023]\]. In mouse cells, bFGF-induced phosphorylation of MEK and ERK was observed, but Akt phosphorylation was not \[[@pone.0141581.ref023]\]. Therefore, MEK/ERK pathways are considered to play a central role in bFGF-induced neuronal differentiation. In contrast, in our study, PI3K and Akt inhibitors clearly attenuated bFGF-induced neuronal marker expression and morphological change in canine BMSCs, but the MEK/ERK inhibitor did not show this effect. Furthermore, we confirmed that bFGF induces the phosphorylation of Akt through FGFR and PI3K. These results strongly suggest that the PI3K/Akt pathway contributes to the bFGF-induced neuronal differentiation of canine BMSCs. The PI3K/Akt pathway has been shown to play important roles in the regulation of cytoskeletal rearrangement, membrane expansion, transcription, and translation \[[@pone.0141581.ref047]\]. PI3K plays a fundamental role in regulating neuronal generation through the activation of Akt \[[@pone.0141581.ref048], [@pone.0141581.ref049]\]. PI3K phosphorylates the membrane phospholipid phosphatidylinositol 4,5-phosphate (PIP~2~), converting it to phosphatidylinositol 3,4,5-trisphosphate (PIP~3~). PIP~2~ and PIP~3~ in turn cause the activation of Akt \[[@pone.0141581.ref047], [@pone.0141581.ref050]\]. The accumulation of PIP~3~ promotes the translocation of Akt to the plasma membrane, where Akt binds to PIP~3~ via its PH domain, allowing phosphorylation of the threonine-308 residue on Akt by phosphoinositide-dependent kinase 1. The maximal activation of Akt requires the additional phosphorylation of serine-473 in the regulatory domain, although protein kinases involved in this phosphorylation are still obscure \[[@pone.0141581.ref051]--[@pone.0141581.ref053]\]. The constitutively active form of Akt initiates neurite elongation only in early differentiation stages \[[@pone.0141581.ref054]\]. The overexpression of constitutively active Akt induces neurite outgrowth and the expression of neuronal markers \[[@pone.0141581.ref007], [@pone.0141581.ref039]\]. Activated Akt promotes neuronal differentiation in neural stem cells \[[@pone.0141581.ref049], [@pone.0141581.ref055], [@pone.0141581.ref056]\]. It is therefore conceivable that PI3K/Akt pathway contributes to neuronal differentiation in canine BMSCs.

To investigate whether FGFR-2 activates the PI3K/Akt signaling pathway, we performed a FGFR-2 knockdown experiment using the transfection of FGFR-2 siRNA. We showed that knocking down FGFR-2 clearly inhibited bFGF-induced Akt phosphorylation. These observations strongly suggest that FGFR-2 has a crucial function, via the PI3K/Akt pathway, in the neuronal differentiation of canine BMSCs. On the other hand, bFGF has been reported to bind to FGFR-1 and play a central role in the bFGF-induced neuronal differentiation of mouse BMSCs via the MEK/ERK signaling pathway \[[@pone.0141581.ref023]\]. Therefore, FGFR expression patterns and the binding affinity of bFGF to FGFRs appear to be attributable to the selection of signaling pathways.

The downstream target of the FGFR-2/PI3K/Akt pathway in bFGF-induced neuronal differentiation of canine BMSCs is still obscure. In mouse BMSCs, bFGF-induced activation of the MEK/ERK pathway has been reported to activate transcription factor AP-1, which is subsequently involved in neuronal differentiation \[[@pone.0141581.ref023]\]. We therefore examined the effect of bFGF on AP-1 activation in canine BMSCs. However, we observed that bFGF had no effect on the activation of AP-1 (data not shown), suggesting that transcription factors distinct from AP-1 are a downstream target of the FGFR-2/PI3K/Akt pathway. Akt phosphorylates and inhibits glycogen synthase kinase-3β (GSK-3β); this inhibition leads to the activation of a transcriptional co-activator β-catenin, which consequently induces neuronal differentiation. In human neural stem cells, the GSK-3β/β-catenin pathway is involved in motor neuron differentiation \[[@pone.0141581.ref057]--[@pone.0141581.ref060]\]. This pathway also mediates neuronal differentiation in human BMSCs \[[@pone.0141581.ref061], [@pone.0141581.ref062]\]. The mammalian target of rapamycin (mTOR) is also in a pathway downstream of Akt. In human neural progenitor cells, mTOR activates P70S6K, and consequently induces neuronal differentiation, although P70S6K targets involved in this process have not been investigated in detail \[[@pone.0141581.ref063]\]. In canine adipose-derived stem cells, mTOR/p70S6K activation stimulated by PI3K/Akt participates in neuronal differentiation \[[@pone.0141581.ref064]\]. Therefore, we hypothesize that such factors are may mediate the neuronal differentiation of canine BMSCs. Further study of this possibility is underway in our laboratory.

Currently, only bFGF has been reported to induce the differentiation of human BMSCs into dopaminergic neurons. However, the downstream signaling of bFGF in this process is obscure \[[@pone.0141581.ref027]\]. In human BMSCs, multiple signaling pathways, including MEK/ERK and PI3K/Akt, have been reported to regulate neuronal differentiation \[[@pone.0141581.ref065]\]. In mice, bFGF has been shown to induce the activation of the FGFR-1/MEK/ERK pathway but not the PI3K/Akt pathway in BMSCs \[[@pone.0141581.ref023]\]. In the present study, we demonstrated the activation of FGFR-2/PI3K/Akt signaling in bFGF-treated canine BMSCs. The previous reports and our observations suggest that differences in signal transduction mechanisms in neuronal differentiation are probably dependent on species, intrinsic cellular processes, and the extracellular microenvironment. Therefore, we hypothesize that canine models could partially mimic aspects of human neuronal differentiation, making canine BMSCs useful as a model to understand the mechanisms of neuronal differentiation and its regeneration in humans.

In human BMSCs, not only bFGF but also neurotrophins (NTs), glial cell line-derived neurotrophic factor (GDNF) and Wnt have been reported to induce the differentiation into neurons \[[@pone.0141581.ref024], [@pone.0141581.ref062], [@pone.0141581.ref067]--[@pone.0141581.ref070]\]. NTs including nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, neurotrophin-4/5, promote the survival and growth of developing neurons, and axon regrowth in SCI, maintain the function of mature neurons, and prevent neuron death. Neurotrophin-3 induced the differentiation of human BMSCs into GABAergic neuron, which exhibited spontaneous post-synaptic currents, but none of them exerted action potentials \[[@pone.0141581.ref068]--[@pone.0141581.ref070]\]. Nerve growth factor and brain-derived neurotrophic factor induced the differentiation of human BMSCs into cholinergic neuron-like cells in the presence of Wnt 7a \[[@pone.0141581.ref062]\]. GDNF, involving with the generation and development of midbrain dopaminergic neurons, induced the expression of dopaminergic neuron markers in human BMSCs \[[@pone.0141581.ref024], [@pone.0141581.ref067]\]. Contribution of epidermal growth factor, Sonic hedgehog, FGF-8, and all-trans retinoic acid to the differentiation of human BMSCs into dopaminergic neuron-like cells in the presence or absence of bFGF has also been reported \[[@pone.0141581.ref027], [@pone.0141581.ref066]\]. These observations imply that such exogenous factors affect intracellular signaling pathways, which results in the differentiation of BMSCs into specific neurotransmitter-responsive or neurotransmitter-supplying neurons. It may facilitate the treatment of neuronal diseases to provide such specific neurons derived from BMSCs by activating signaling pathways. Therefore, the results of this study could further the future use of BMSCs in cellular replacement therapy.

Conclusions {#sec019}
===========

In conclusion, we demonstrated that the FGFR-2/PI3K/Akt pathway contributes to bFGF-induced neuronal differentiation of canine BMSCs. Our results provide new insights into the bFGF-induced neuronal differentiation mechanism, and may enable the development of new cell-based treatments for neuronal diseases.
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